<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501926</url>
  </required_header>
  <id_info>
    <org_study_id>PI-29/17</org_study_id>
    <nct_id>NCT04501926</nct_id>
  </id_info>
  <brief_title>Genomics and Metagenomics of Asthma Severity</brief_title>
  <acronym>GEMAS</acronym>
  <official_title>Genomics and Metagenomics of Asthma Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Pino-Yanes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of La Laguna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Ministry of Science, Innovation, and Universities</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorcio Centro de Investigación Biomédica en Red, M.P.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of the Nuestra Señora de Candelaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General de La Palma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Donostia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Doctor Jose Molina Orosa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of La Laguna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Genomics and Metagenomics of Asthma Severity (GEMAS) study aims to assess the role of&#xD;
      genomics, the microbiome, and the interaction between them in the development of asthma&#xD;
      exacerbations in European patients with asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a chronic inflammatory disease of the airways characterized by reversible airflow&#xD;
      obstruction and a bronchial hyperreactivity in response to a variety of stimuli. In most&#xD;
      patients, the onset of asthma symptoms may be controlled. However, many of them may manifest&#xD;
      asthma attacks or crises of breathing called exacerbations, which occur with breathing&#xD;
      problems, wheezing, coughing or tightness of chest, and may threaten their life. Such&#xD;
      exacerbations are caused by a combination of environmental and genetic factors. However,&#xD;
      since studies so far have been limited, a reduced number of genes associated with the&#xD;
      predisposition to these complications have been identified. In addition, some studies have&#xD;
      used next-generation DNA sequencing techniques to characterize the microbiome (i.e.,&#xD;
      microbial community) of the airways, finding changes related to asthma. The main hypothesis&#xD;
      of the Genomics and Metagenomics of Asthma Severity (GEMAS) study is that exacerbations of&#xD;
      asthma are caused by a combination of the intrinsic genetic factors of the individual,&#xD;
      changes in the respiratory microbiome and the interaction between both factors. The&#xD;
      objectives of this project are: 1) to identify genetic variants that are associated with&#xD;
      asthma exacerbations; 2) to examine the changes occurring in the microbial communities of the&#xD;
      oral cavity and respiratory tract in individuals with exacerbations; 3) to analyze the&#xD;
      association of the host genetic variants and the microbiome changes related to exacerbations.&#xD;
&#xD;
      A total of 300 Spanish subjects with asthma with and without a history of asthma&#xD;
      exacerbations in the past 12 months will be recruited. Saliva, nasal and pharyngeal samples&#xD;
      will be collected to study the oral cavity and the upper respiratory tract microbiome through&#xD;
      next-generation sequencing technologies. Sequencing of the 16S ribosomal RNA (16S rRNA) gene&#xD;
      will allow to characterize the bacterial diversity and abundance, as well as to infer the&#xD;
      functionality of the microbiome in each sample. These parameters will be used to establish&#xD;
      correlations between the microbiome and the presence of asthma exacerbations. Finally, the&#xD;
      association between the genetic variation associated with exacerbations in genomic studies&#xD;
      and the measurements of abundance, diversity and functions related to exacerbations will be&#xD;
      jointly examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severe asthma exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Defined by one of the following events because of asthma during the past year, the past 6 months, and the past week: oral corticosteroids use, emergency room visit, and/or hospitalizations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma control</measure>
    <time_frame>1 week</time_frame>
    <description>Asthma control questionnaire (ACQ) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma severity</measure>
    <time_frame>1 year</time_frame>
    <description>Category of severity defined by treatment step according to GINA 2020 at recruitment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function measurement: forced expiratory volume in the first second (FEV1)</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline and post-bronchodilator measurements of the forced expiratory volume in the first second (FEV1) measured in liters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function measurement: forced vital capacity (FVC)</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline and post-bronchodilator measurements of the forced vital capacity (FVC) measured in liters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function measurement: FEV1/FVC ratio</measure>
    <time_frame>3 months</time_frame>
    <description>The ratio of FEV1/FVC measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atopy testing</measure>
    <time_frame>1 year</time_frame>
    <description>Atopy status evaluated by skin prick tests and/or specific immunoglobulin E (IgE) levels assessing the most common aeroallergens of each recruiting center</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Asthma</condition>
  <condition>Asthma Attack</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Asthma patients who did not report asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Asthma patients that reported asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are drown in EDTA tubes and PAXGene tubes for human DNA and RNA extraction,&#xD;
      respectively. For the human microbiome study, saliva samples and nasal and pharyngeal swaps&#xD;
      are collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are recruited from the allergy and/or pulmonary medicine units from hospitals&#xD;
        located in the Canary Islands, Spain (Hospital Universitario de Canarias, Hospital&#xD;
        Universitario Nuestra Señora de Candelaria, Hospital General de La Palma, and Hospital&#xD;
        Doctor Jose Molina Orosa), and in the division of pediatric respiratory medicine of&#xD;
        Hospital Universitario Donostia in the Basque Country, Spain.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged older or equal than 8 years and younger or equal than 85 years&#xD;
&#xD;
          -  Physician diagnosis of asthma according to the Global Initiative for Asthma (GINA)&#xD;
             guidelines&#xD;
&#xD;
          -  Treated on GINA step 1-5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  One or more grandparents of non-European origin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Coexistence of other chronic pulmonary disorders including cystic fibrosis, chronic&#xD;
             obstructive pulmonary disease (emphysema or chronic bronchitis), or congenital&#xD;
             disorders of the lungs or airways&#xD;
&#xD;
          -  Known family relatedness (first or second degree) with another participant already&#xD;
             included in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Pino-Yanes, Ph.D.</last_name>
    <phone>+34 922 316 502</phone>
    <phone_ext>6343</phone_ext>
    <email>mdelpino@ull.edu.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabian Lorenzo-Diaz, Ph.D.</last_name>
    <phone>+34 922 316 502</phone>
    <phone_ext>8350</phone_ext>
    <email>florenzo@ull.edu.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of La Laguna</name>
      <address>
        <city>San Cristobal de la Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Jose Molina Orosa</name>
      <address>
        <city>Arrecife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berta Roman-Bernal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de La Palma</name>
      <address>
        <city>Breña Alta</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Hernandez-Perez, MD, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>San Cristobal de la Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruperto Gonzalez-Perez, MD, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaia Sardon, MD, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Hernandez-Perez, MD, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of La Laguna</investigator_affiliation>
    <investigator_full_name>Maria Pino-Yanes</investigator_full_name>
    <investigator_title>Ramon y Cajal Fellow and Lecturer</investigator_title>
  </responsible_party>
  <keyword>Genome-Wide Association Study</keyword>
  <keyword>Microbiome, Human</keyword>
  <keyword>Asthma</keyword>
  <keyword>Epigenomics</keyword>
  <keyword>Transcriptomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

